Anabio R&D
11
1
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia
Role: lead
Oral-Spray Bacillus Spore Probiotics for Periodontal Disease Prevention and Supprotive Treatment in the Elderly
Role: lead
Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates
Role: lead
Oral-Spray Bacillus Spore Probiotic in Preventing and Supporting Treatment of Dental Caries in Children
Role: lead
Effects of LiveSpo X-SECRET in SupportiveTreatment of Vaginitis
Role: lead
Efficacy of Probiotics (LiveSpo Navax) in Preventing Respiratory Diseases in Children
Role: lead
Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections
Role: collaborator
Effectiveness of Bacillus Spore Probiotics in Reducing Constipation, Anorexia, and Slow Weight Gain in Children
Role: lead
Efficacy of LiveSpo COLON as a Supportive Treatment for Inflammatory Bowel Disease (IBD)
Role: lead
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
Role: lead
Effects of LiveSpo X-secret in Supporting Treatment of Sexually Transmitted Diseases
Role: lead
All 11 trials loaded